New Aspects of Pulmonary Tuberculosis

Year 2020, , 23 - 26, 30.04.2020

Nesrin Sarıman , Selim Nalbant

https://doi.org/10.35514/mtd.2020.25

Abstract

There is a worldwide rise in tuberculosis (TB) cases with drug resistant strains being a threat to disease control with the current measures. In recent years novel antituberculosis drug candidates and vaccines have entered clinical trials. Besides their activity against multi drug and extensively drug resistant strains they also target to reduce the treatment period and dosing. In this article recent developments in tuberculosis diagnostics, new anti tuberculosis drugs and vaccines for tuberculosis have been summarized.

Keywords

pulmonary tuberculosis, new antituberculosis drugs, drug resistance, vaccination

Pulmoner Tüberküloza Yeni Bakışaçısı

Abstract

There is a worldwide rise in tuberculosis (TB) cases with drug resistant strains being a threat to disease control with the current measures. In recent years novel antituberculosis drug candidates and vaccines have entered clinical trials. Besides their activity against multi drug and extensively drug resistant strains they also target to reduce the treatment period and dosing. In this article recent developments in tuberculosis diagnostics, new anti tuberculosis drugs and vaccines for tuberculosis have been summarized.

Keywords

pulmonary tuberculosis, new antitubrerculosis drugs, drug resistance, vaccination

References

• 1-WHO. Global tuberculosis report 2014. World Health Organization, Geneva (2014) http://www.who.int/tb/publications/global_report/en/ (accessed Nov 12, 2014).
• 2-Ralph AP, Anstey NM, Kelly PM. Tuberculosis into the 2010s: Is the Glass Half Full? Clin Infect Dis. 2009; 49 (4): 574-583.
• 3-Amicosante M, Ciccozzi M, Markova R. Rational use of immunodiagnostic tools for tuberculosis infection: guidelines and cost effectiveness studies. New Microbiol 2010; 33 (2):93-107.
• 4-Weiner J 3rd, Kaufmann SH. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med. 2014;275(5):467-480. doi: 10.1111/joim.12212.
• 5-Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy.Drug Discov Today 2006 ;11(1-2):21-27.
• 6-Lougheed KE, Taylor DL, Osborne SA, Bryans JS, Buxton RS. New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb). 2009 Sep;89(5):364-370. doi: 10.1016/j.tube.2009.07.002.
• 7-Balganesh TS, Alzari PM, Cole ST. Rising standards for tuberculosis drug development. Trends Pharmacol Sci 2008 Nov;29(11):576-581.
• 8-Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today. 2008 Dec;13(23-24):1090 -1098. doi: 10.1016/j.drudis.2008.09.004.
• 9-Grandjean L, AJ Moore D. Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug resistant tuberculosis (XDR-TB) Curr Opin Infect Dis. 2008; 21(5): 454-461. doi:10.1097/QCO.0b013e32830ce783.
• 10-Janin YL. Antituberculosis drugs: Ten years of research .Bioorg Med Chem 2007; 1;15(7):2479-513.
• 111-The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization; 2013. WHO Guidelines Approved by the Guidelines Review Committee
• 12-Kaufman SH, Weiner J, von Reyn CF. Novel approaches to tuberculosis vaccine developmentInt Int J Infect Dis . 2017; 56: 263-267. doi: 10.1016/j.ijid.2016.10.018